Didier Meulendijks
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
Dec 12, 2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Dec 12, 2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950.
Nov 20, 2019Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Nov 20, 2019CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950
Jacobs Bart A W, Deenen Maarten J, Joerger Markus, Rosing Hilde, de Vries Niels, Meulendijks Didier, Cats Annemieke, Beijnen Jos H, Schellens Jan H M, Huitema Alwin D R